CURX

Peers: ABVC JAGX EDSA HIND PALI DRMA IGC KAPA SPRC ENTX

Index	-
Market Cap	7.86M
Enterprise Value	5.20M
Income	-10.47M
Sales	0.00M
Book/sh	3.38
Cash/sh	1.87
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	6
IPO	Aug 26, 2025

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.48
P/C	2.67
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	45.95
Current Ratio	45.95
Debt/Eq	0.06
LT Debt/Eq	0.04
Option/Short	No / Yes

EPS (ttm)	-7.38
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	-1369.89% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-2256.41%
Sales Y/Y TTM	-
EPS Q/Q	-5246.54%
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	61.35%
Insider Trans	0.00%
Inst Own	1.07%
Inst Trans	1.07%
ROA	-357.22%
ROE	-411.08%
ROIC	-210.65%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	3.12%
SMA50	7.11%
SMA200	-20.05%
Trades

Shs Outstand	1.42M
Shs Float	0.61M
Short Float	0.51%
Short Ratio	0.15
Short Interest	0.00M
52W High	16.93 -70.41%
52W Low	3.58 40.10%
Volatility	8.36% 9.45%
ATR (14)	0.47
RSI (14)	54.20
Beta	-2.86
Rel Volume	0.00
Avg Volume	20.86K
Volume	0

Perf Week	1.01%
Perf Month	9.39%
Perf Quarter	25.25%
Perf Half Y	-42.68%
Perf YTD	-24.23%
Perf Year	-57.10%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	5.01
Price	5.01
Change %	0.00%

May-14-26 08:53AM	Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission (GlobeNewswire)
Apr-08-26 07:47AM	Curanex Highlights Five Additional Patient Cases Further Supporting the Potential of Its Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic Decline (GlobeNewswire)
Apr-06-26 09:17AM	Curanex Highlights Patient Case Study Supporting Potential of Phyto-N in Cancer Cachexia and Advanced Cancer Supportive Care (GlobeNewswire) +7.94%
Apr-02-26 08:07AM	Curanex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important Step In The Company's Evolution Into a Broader Therapeutics Development Company (GlobeNewswire)
Mar-30-26 05:35PM	Curanex Provides Business Update in Connection with 2025 Annual Report as Phyto-N Advances Toward Planned IND Submission (GlobeNewswire)
08:00AM	Loading…
Mar-18-26 08:00AM	Curanex Achieves Key Preclinical Milestone with Favorable Toxicology Profile at Maximum Dose, Advancing Toward IND Submission (GlobeNewswire) +10.43%
Mar-12-26 09:30AM	Curanex Expands Scientific Advisory Board With Two Distinguished Researchers (GlobeNewswire) -11.59%
Mar-11-26 08:00AM	Curanex Appoints Two Veteran Industry Leaders to Scientific Advisory Board (GlobeNewswire) +6.16%
Mar-05-26 08:00AM	Curanex Forms World Class Scientific Advisory Board (GlobeNewswire)
Feb-26-26 02:11AM	What's Behind Curanex Pharmaceuticals (CURX) 56% Surge After Hours (Benzinga) +45.77%
Feb-25-26 08:00AM	Curanex Provides Operational Update on Key Regulatory Milestones (GlobeNewswire)
Oct-22-25 07:00AM	Curanex Pharmaceuticals Inc. Engages Strategic Investor Relations to Enhance Investor Communications and Engagement (GlobeNewswire) +14.39%
Sep-12-25 02:46PM	Curanex Pharmaceuticals Inc. Announces Exercise of the Over-Allotment Option by Underwriters (GlobeNewswire)
Aug-27-25 05:00PM	Curanex Pharmaceuticals Inc. Announces Closing of its Initial Public Offering (GlobeNewswire) +15.92% +11.37%
Aug-26-25 07:30AM	Curanex Pharmaceuticals Inc. Announces Pricing of its Initial Public Offering (GlobeNewswire)

Curanex Pharmaceuticals, Inc. engages in the pharmaceutical business. It focuses on developing and commercializing botanical treatments for inflammatory diseases. The company was founded by Ying Jing and Chang Liu in 1996 and is headquartered in Jericho, NY.

CEOMr. Jun Liu

Chief Financial Officer & TreasurerMr. Wanjun Zhang

Chief Operating OfficerDr. Liqin Xie Ph.D.

Chief Technology OfficerDr. Ning Zhang Ph.D.

Chief Science Officer & DirectorDr. Huijuan Zhong Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Curanex Pharmaceuticals Inc

Upgrade your Finviz experience